

Supplemental Material 1. Search strategy

Supplemental Material 2. Funnel plot of BCVA change

Supplemental Material 3. Funnel plot of CRT change

Supplemental Material 4. Funnel plot of IOP change

Supplemental Material 5. Funnel plot of SAE occurrence

Supplemental Material 6. BCVA change – subgroup analysis of nonresistant DME patients

Supplemental Material 7. BCVA change – meta-regression

Supplemental Material 8. CRT change – subgroup analysis of nonresistant DME patients

Supplemental Material 9. CRT change – meta-regression

Supplemental Material 10. Forest plot of IOP change and subgroup analysis of nonresistant DME patients

Supplemental Material 11. IOP change – meta-regression

Supplemental Material 12. Severe ocular adverse events and subgroup analysis of nonresistant DME patients

Supplemental Material 13. Risk of bias assessment (ROB)

Supplemental Material 14. Risk of bias assessment ROBINS-1 (BCVA)

Supplemental Material 15. Subgroup analysis - type of Anti-vegf - BCVA change

Supplemental Material 16. Subgroup analysis - type of Anti-vegf - CRT decrease

Supplemental Material 17. Subgroup analysis - study design - BCVA change

Supplemental Material 18. Subgroup analysis - study design - CRT decrease

Supplemental Material 19. Summary of OCT biomarker



Supplemental Material 1 Search strategy

Primary search steps:

#1 anti- vascular endothelial growth factors

#2 anti-VEGF

#3 ranibizumab

#4 lucentis

#5 aflibercept

#6 eylea

#7 bevacizumab

#8 avastin

#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8

#10 ozurdex

#11 intravitreal dexamethasone implant

#12 dexamethasone

#13 #10 OR #11 OR #12

#14 diabetic retinopathy

#15 diabetic macular edema

#16 DME

#17 DMO

#18 cystoid macular edema

#19 CME


#20 #16 OR #17 OR #18 OR #19

#21 #9 AND #13 AND #20

Final syntax in PubMed (an example):




Funnel plot of BCVA change






Funnel plot of CRT change






Funnel plot of IOP change





Funnel plot of SAE occurrence







BCVA change – subgroup analysis of nonresistant DME patients

| | Expe | rimental | | | Control | | BCVA change | | | |
|---------------------------------|--------------------------|-----------------------|-------|-------|---------|-------|------------------------------|-------|----------------|--------|
| Study | Mean | SD | Total | Mean | SD | Total | (By combined medication) | MD | 95%-CI | Weight |
| Subgroup: Anti-VE | GF vs Ozurdex | alone | | | | | Ī | | | |
| Aydin | -0.55 | 0.17 | 37 | -0.14 | 0.13 | 28 | - | -0.41 | [-0.48; -0.34] | 5.1% |
| Mishra | -0.23 | 0.32 | 50 | -0.10 | 0.41 | 50 | | -0.13 | [-0.27; 0.01] | 4.5% |
| Gilles | -0.18 | 0.18 | 42 | -0.11 | 0.33 | 46 | | -0.07 | [-0.18; 0.04] | 4.8% |
| Ozsaygili | -0.19 | 0.04 | 50 | -0.13 | 0.07 | 48 | | -0.06 | [-0.08; -0.04] | 5.3% |
| Podkowinski | -0.20 | 0.25 | 9 | -0.15 | 0.23 | 5 | | -0.05 | [-0.31; 0.21] | 3.3% |
| Sever | -0.11 | 0.06 | 44 | -0.06 | 0.05 | 40 | | -0.05 | [-0.07; -0.03] | 5.3% |
| Shin | -0.23 | 0.20 | 25 | -0.22 | 0.29 | 20 | - | -0.01 | [-0.16; 0.14] | 4.4% |
| Vujosevic | -0.13 | 0.15 | 26 | -0.13 | 0.17 | 23 | - <u>ii</u> - | 0.00 | [-0.09; 0.09] | 5.0% |
| Shah | -0.11 | 0.12 | 23 | -0.12 | 0.15 | 27 | - | 0.01 | [-0.06; 0.08] | 5.1% |
| Routier | -0.13 | 0.05 | 37 | -0.16 | 0.05 | 5 | T- | 0.03 | [-0.02; 0.08] | 5.2% |
| Ceravolo | -0.11 | 0.35 | 75 | -0.15 | 0.34 | 81 | | 0.04 | [-0.07; 0.15] | 4.8% |
| Comet(L) | -0.14 | 0.24 | 19 | -0.19 | 0.22 | 21 | - | 0.05 | [-0.09; 0.19] | 4.5% |
| Muftuoglu | -0.09 | 0.08 | 18 | -0.16 | 0.06 | 19 | | 0.07 | [0.02; 0.12] | 5.2% |
| Demircan | -0.10 | 0.30 | 101 | -0.20 | 0.30 | 35 | | 0.10 | [-0.02; 0.22] | 4.7% |
| Mastropasqua | -0.10 | 0.35 | 9 | -0.20 | 0.10 | 13 | | 0.10 | [-0.14; 0.34] | 3.5% |
| Bolubasi | -0.30 | 0.25 | 32 | -0.40 | 0.25 | 25 | - | 0.10 | [-0.03; 0.23] | 4.6% |
| Subtotal | | | 597 | | | 486 | | -0.02 | [-0.09; 0.05] | 75.4% |
| Heterogeneity: $I^2 = 90^\circ$ | %, p < 0.01 | | | | | | | | | |
| Subgroup: Anti-VE | GF vs Ozurdex | +Anti-VEGF | 8 | | | | | | | |
| Hernández-Bel | -0.25 | 0.05 | 15 | -0.22 | 0.04 | 15 | | -0.03 | [-0.06; 0.00] | 5.3% |
| lin | -0.10 | 0.34 | 50 | -0.09 | 0.45 | 52 | -1- | -0.01 | [-0.16; 0.14] | 4.4% |
| Maturi (2018) | -0.06 | 0.14 | 64 | -0.05 | 0.20 | 63 | - | -0.01 | [-0.07; 0.05] | 5.2% |
| Maturi (2015) | -0.10 | 0.25 | 19 | -0.11 | 0.21 | 20 | - - | 0.01 | [-0.14; 0.16] | 4.5% |
| Kaya | -0.19 | 0.02 | 34 | -0.43 | 0.04 | 34 | T | 0.24 | [0.22; 0.26] | 5.3% |
| Subtotal | | | 182 | | | 184 | | 0.04 | [-0.10; 0.19] | 24.6% |
| Heterogeneity: $I^2 = 99$ | %, p < 0.01 | | | | | | | | | |
| Overall | | | 779 | | | 670 | 1 | -0.00 | [-0.06; 0.05] | 100.0% |
| Heterogeneity: $I^2 = 98$ | % p < 0.01 | | | | | | | | | |
| Test for subgroup diffe | erences: $\chi^2 = 1.19$ | 9, $df = 1$ ($p = 0$ | 0.27) | | | | -0.4-0.2 0 0.2 0.4 0.6 0.8 1 | | | |

Supplemental Material 7
BCVA change –
meta-regression








CRT change -


subgroup analysis of nonresistant DME patients




Supplemental Material 9
CRT change –
meta-regression

Supplemental Material 9 CRT change -

meta-regression






Forest plot of IOP change and subgroup analysis of nonresistant DME patients


| | Expe | rimental | | | Control | | IOP change | | | |
|------------------------------------------------------------------|------------------------------|-----------------|------------|-------|---------|-------|------------------|------------|----------------|--------|
| Study | Mean | SD | Total | Mean | SD | Total | (By resistant) | MD | 95%-CI | Weight |
| Subgroup: non-resis | stant | | | | | | 1.1 | | | |
| Shah | -0.70 | 2.50 | 23 | 1.10 | 3.90 | 27 | | -1.80 | [-3.59; -0.01] | 6.5% |
| Wickranasingle | -1.30 | 5.70 | 22 | -0.20 | 3.80 | 22 - | | -1.10 | [-3.96; 1.76] | 3.0% |
| Aydin | 0.80 | 1.43 | 37 | 1.80 | 1.30 | 28 | - | -1.00 | [-1.67; -0.33] | 19.1% |
| Muftuoglu | -0.45 | 2.07 | 18 | 0.37 | 2.18 | 19 | | -0.82 | [-2.19; 0.55] | 9.6% |
| lin | 0.00 | 4.22 | 50 | 0.40 | 3.36 | 52 | | -0.40 | [-1.88; 1.08] | 8.6% |
| Bolubasi | 0.40 | 2.55 | 32 | 0.30 | 2.81 | 25 | | 0.10 | [-1.31; 1.51] | 9.2% |
| Shin | 0.40 | 2.67 | 25 | 0.10 | 2.74 | 20 | | - 0.30 | [-1.29; 1.89] | 7.8% |
| Karakurt(L) | 0.08 | 2.58 | 81 | -0.28 | 2.16 | 54 | | 0.36 | [-0.44; 1.16] | 16.7% |
| Sever | 0.50 | 3.01 | 44 | -0.10 | 2.85 | 40 | 41- | - 0.60 | [-0.65; 1.85] | 10.7% |
| Subtotal | | | 332 | | | 287 | | -0.33 | [-0.92; 0.27] | 91.2% |
| Heterogeneity: $I^2 = 39\%$ | $b_{i}p = 0.11$ | | | | | | | | | |
| Subgroup: resistant | | | | | | | | | | |
| Sharma | -1.57 | 2.35 | 20 | -0.17 | 2.34 | 20 | | -1.40 | [-2.85; 0.05] | 8.8% |
| Overall Heterogeneity: $I^2 = 40\%$ Test for subgroup difference | p = 0.09 ences: 2 = 1.87 | ' df = 1 (n = (| 352 | | | 307 | -3 -2 -1 0 1 | -0.42 2 | [-1.00; 0.15] | 100.0% |
| reaction dubgroup differ | 011000. | , a (p - c | 2.17) | | | | -5 -2 -1 0 1 | 2 | | |


| | Expe | rimental | | | Control | | IOP change | | | |
|---------------------------------------------------------------------------------|---------------------|-----------------|-------|-------|---------|-------|----------------------------|-------|----------------|--------|
| Study | Mean | SD | Total | Mean | SD | Total | (By combined medication) | MD | 95%-CI | Weight |
| Subgroup: Anti-VE | GF vs Ozurdex | alone | | | | | 11 | | | |
| Shah | -0.70 | 2.50 | 23 | 1.10 | 3.90 | 27 | | -1.80 | [-3.59; -0.01] | 7.1% |
| Wickranasingle | -1.30 | 5.70 | 22 | -0.20 | 3.80 | 22 | | -1.10 | [-3.96; 1.76] | 3.2% |
| Aydin | 0.80 | 1.43 | 37 | 1.80 | 1.30 | 28 | | -1.00 | [-1.67; -0.33] | 21.2% |
| Muftuoglu | -0.45 | 2.07 | 18 | 0.37 | 2.18 | 19 | | -0.82 | [-2.19; 0.55] | 10.4% |
| Bolubasi | 0.40 | 2.55 | 32 | 0.30 | 2.81 | 25 | | 0.10 | [-1.31; 1.51] | 10.0% |
| Shin | 0.40 | 2.67 | 25 | 0.10 | 2.74 | 20 | | 0.30 | [-1.29; 1.89] | 8.5% |
| Karakurt(L) | 0.08 | 2.58 | 81 | -0.28 | 2.16 | 54 | | 0.36 | [-0.44; 1.16] | 18.5% |
| Sever | 0.50 | 3.01 | 44 | -0.10 | 2.85 | 40 | | 0.60 | [-0.65; 1.85] | 11.7% |
| Subtotal | | | 282 | | | 235 | | -0.32 | [-1.01; 0.37] | 90.6% |
| Heterogeneity: $I^2 = 47^\circ$ | $%_{,} \rho = 0.07$ | | | | | | | | | |
| Subgroup: Anti-VE | GF vs Ozurdex | +Anti-VEGF | : | | | | | | | |
| lin | 0.00 | 4.22 | 50 | 0.40 | 3.36 | 52 | | -0.40 | [-1.88; 1.08] | 9.4% |
| Overall Heterogeneity: I ² = 39 ⁴ Test for subgroup diffe | | 1 df = 1 (p = (| 332 | | | 287 | 3 -2 -1 0 1 2 | -0.33 | [-0.92; 0.27] | 100.0% |
| root for outgroup unio | 1011000. | ., a | 3.52) | | | | -5 -2 -1 0 1 2 | | | |



IOP change – meta-regression










Severe ocular adverse events and subgroup analysis of nonresistant DME patients

| | Exp | erimental | | Control | Serious adverse event | | | |
|----------------------------|-----------------------------|-------------------|--------|---------|-----------------------|------|---------------|--------|
| Study | Events | Total | Events | Total | (By resistant) | RR | 95%-CI | Weight |
| Subgroup: non-res | istant | | | | 11 | | | |
| Callanan | 0.0 | 182.0 | 11.0 | 181.0 | ← ■ | 0.04 | [0.00; 0.73] | 10.5% |
| Maturi (2018) | 0.0 | 64.0 | 6.0 | 65.0 | | 0.08 | [0.00; 1.36] | 10.3% |
| Aydin | 0.5 | 37.5 | 0.5 | 28.5 | 8 22 | 0.76 | [0.02; 37.16] | 5.5% |
| Ozsaygili | 0.5 | 50.5 | 0.5 | 48.5 | | 0.96 | [0.02; 47.45] | 5.5% |
| Kaya | 0.5 | 34.5 | 0.5 | 34.5 | | 1.00 | [0.02; 48.98] | 5.5% |
| Maturi (2015) | 0.5 | 20.5 | 0.5 | 20.5 | | 1.00 | [0.02; 48.03] | 5.6% |
| Comet(L) | 0.5 | 20.5 | 0.5 | 21.5 | | 1.05 | [0.02; 50.43] | 5.6% |
| Muftuoglu | 0.5 | 18.5 | 0.5 | 19.5 | | 1.05 | [0.02; 50.43] | 5.6% |
| Shah | 3.0 | 23.0 | 2.0 | 27.0 | | 1.76 | [0.32; 9.64] | 29.0% |
| Subtotal | | 451.0 | | 446.0 | | 0.56 | [0.18; 1.72] | 83.2% |
| Heterogeneity: $I^2 = 8\%$ | $p_{i} p = 0.37$ | | | | | | | |
| Subgroup: resistan | t | | | | | | | |
| Limon | 0.5 | 30.5 | 0.5 | 29.5 | | 0.97 | [0.02; 47.17] | 5.5% |
| Sharma | 0.5 | 20.5 | 0.5 | 20.5 | | 1.00 | [0.02; 48.03] | 5.6% |
| Thomas | 0.5 | 11.5 | 0.5 | 11.5 | | 1.00 | [0.02; 46.24] | 5.7% |
| Subtotal | | 62.5 | | 61.5 | | 0.99 | [0.94; 1.04] | 16.8% |
| Heterogeneity: $I^2 = 0\%$ | p = 1.00 | | | | | | | |
| Overall | | 513.5 | | 507.5 | - | 0.64 | [0.28; 1.49] | 100.0% |
| Heterogeneity: $I^2 = 0\%$ | p = 0.63 | | | | | 1 | | |
| Test for subgroup diffe | rences: $\chi_1^2 = 1.36$, | df = 1 (p = 0.24) | 1) | 0.0 | 003 0.1 0.51 2 10 5 | 51 | | |

| | Exp | erimental | | Control | Serious adverse event | | | |
|----------------------------|------------------------------|-------------------|--------|---------|----------------------------|----|---------|--------|
| Study | Events | Total | Events | Total | (By combined medication) | RR | 95%-CI | Weight |
| Subgroup: Anti-VE | GF vs Ozurdex a | lone | | | l i | | | |
| Callanan | 0.0 | 182.0 | 11.0 | 181.0 | ← | 0 | [0; 1] | 13.1% |
| Aydin | 0.5 | 37.5 | 0.5 | 28.5 | | 1 | [0; 37] | 7.2% |
| Ozsaygili | 0.5 | 50.5 | 0.5 | 48.5 | | 1 | [0;47] | 7.2% |
| Comet(L) | 0.5 | 20.5 | 0.5 | 21.5 | | 1 | [0; 50] | 7.3% |
| Muftuoglu | 0.5 | 18.5 | 0.5 | 19.5 | | 1 | [0; 50] | 7.3% |
| Shah | 3.0 | 23.0 | 2.0 | 27.0 | | 2 | [0; 10] | 30.7% |
| Subtotal | | 332.0 | | 326.0 | | 1 | [0; 3] | 72.7% |
| Heterogeneity: $I^2 = 22$ | %, p = 0.27 | | | | | | | |
| Subgroup: Anti-VE | GF vs Ozurdex+ | Anti-VEGF | | | | | | |
| Maturi (2018) | 0.0 | 64.0 | 6.0 | 65.0 | | 0 | [0; 1] | 12.8% |
| Kaya | 0.5 | 34.5 | 0.5 | 34.5 | | 1 | [0;49] | 7.2% |
| Maturi (2015) | 0.5 | 20.5 | 0.5 | 20.5 | | 1 | [0; 48] | 7.3% |
| Subtotal | | 119.0 | | 120.0 | | 0 | [0; 14] | 27.3% |
| Heterogeneity: $I^2 = 0$ % | 6, p = 0.42 | | | | | | | |
| Overall | | 451.0 | | 446.0 | | 1 | [0; 2] | 100.0% |
| Heterogeneity: 12 = 89 | 6 p = 0.37 | | | | | | | |
| Test for subgroup diffe | erences: $\chi_1^2 = 0.56$, | df = 1 (p = 0.45) | 5) | 0. | 003 0.1 0.51 2 10 5 | 1 | | |

Supplemental Material 13
Risk of bias assessment
ROB

Risk of bias assessment (ROB)




Supplemental Material 14
Risk of bias assessment
ROBINS-1 (BCVA)

Risk of bias assessment ROBINS-1 (BCVA)

| Study | Bias due to confounding | Bias in selection of participants into the study | Bias in classification of interventions | Bias due to deviations from intended interventions | Bias due to missing data | Bias in measurement of outcomes | Bias in selection of the reported result | Overall Bias |
|-----------------------|-------------------------|--------------------------------------------------------------|--------------------------------------------------|----------------------------------------------------------------|-----------------------------------|---------------------------------------|---------------------------------------------|-----------------|
| AKSOY 2020 | Serious | Low | Low | NI | Low | Moderate | Moderate | Serious |
| Aydin 2020 | Low | Low | Low | NI | Low | Moderate | Low | Moderate |
| Bolubasi 2019 | Serious | Low | Low | NI | Low | Moderate | Low | Serious |
| Busch 2019 | Moderate | Low | Low | NI | Low | Low | Low | Moderate |
| Ceravolo 2020 | Low | Low | Low | NI | Low | Moderate | Low | Moderate |
| Comet 2020 | Low | Low | Low | Moderate | Low | Moderate | Low | Moderate |
| Demircan 2018 | Serious | Low | Low | NI | Low | Moderate | Low | Serious |
| Hernández-Bel 2019 | Low | Low | Low | NI | Low | Moderate | Low | Moderate |
| Limon 2021 | Low | Low | Low | Low | Low | Moderate | Low | Moderate |
| Lin 2021 | Serious | Low | Low | NI | Low | Moderate | Low | Serious |
| Mastropasqua 2019 | Low | Low | Low | NI | Moderate | Moderate | Low | Moderate |
| Muftuogluet 2021 | Low | Low | Low | Low | Low | Moderate | Low | Moderate |
| Routier 2021 | Serious | Low | Low | NI | Low | Low | Low | Serious |
| Rübsam 2021 | Serious | Low | Low | NI | Low | Low | Low | Serious |
| Sever 2017 | Serious | Low | Low | NI | Low | Moderate | Low | Serious |
| Shin 2017 | Serious | Low | Low | NI | Moderate | Low | Low | Serious |
| Thomas 2016 | Low | Low | Low | NI | Low | Moderate | Low | Moderate |
| Vujosevic 2017 | Serious | Low | Low | Low | Low | Moderate | Low | Serious |


Supplemental Material 15
Subgroup analysis
type of Anti-vegf
BCVA change

Subgroup analysis type of Anti-vegf BCVA change



Subgroup L= Ranibizumab (Lucentis) group Subgroup A= Bevacizumab (Avastin) group Subgroup E= Aflibercept (Eylea) group Supplemental Material 16
Subgroup analysis
type of Anti-vegf
CRT decrease

Subgroup analysis type of Anti-vegf CRT decrease




Subgroup A= Bevacizumab (Avastin) group Subgroup E= Aflibercept (Eylea) group Supplemental Material 17
Subgroup analysis
study design
BCVA change


Supplemental Material 17 Subgroup analysis study design BCVA change

| | Expe | rimental | | | Control | | BCVA change | | | |
|--------------------------|--------------------------------|---------------------|-------|-------|---------|-------|----------------------------|-------|----------------|--------|
| Study | Mean | SD | Total | Mean | SD | Total | (By study design) | MD | 95%-CI | Weight |
| Subgroup: Not RCT | | | | | | | | | | |
| Aydin | -0.55 | 0.17 | 37 | -0.14 | 0.13 | 28 | - | -0.41 | [-0.48; -0.34] | 5.1% |
| Gilles | -0.18 | 0.18 | 42 | -0.11 | 0.33 | 46 | | -0.07 | [-0.18; 0.04] | 4.8% |
| Sever | -0.11 | 0.06 | 44 | -0.06 | 0.05 | 40 | | -0.05 | [-0.07; -0.03] | 5.3% |
| Hernández-Bel | -0.25 | 0.05 | 15 | -0.22 | 0.04 | 15 | | -0.03 | [-0.06; 0.00] | 5.3% |
| Shin | -0.23 | 0.20 | 25 | -0.22 | 0.29 | 20 | - | -0.01 | [-0.16; 0.14] | 4.4% |
| lin | -0.10 | 0.34 | 50 | -0.09 | 0.45 | 52 | | -0.01 | [-0.16; 0.14] | 4.4% |
| Vujosevic (2017) | -0.13 | 0.15 | 26 | -0.13 | 0.17 | 23 | - | 0.00 | [-0.09; 0.09] | 5.0% |
| Routier | -0.13 | 0.05 | 37 | -0.16 | 0.05 | 5 | | 0.03 | [-0.02; 0.08] | 5.2% |
| Ceravolo | -0.11 | 0.35 | 75 | -0.15 | 0.34 | 81 | | 0.04 | [-0.07; 0.15] | 4.8% |
| Comet(L) | -0.14 | 0.24 | 19 | -0.19 | 0.22 | 21 | | 0.05 | [-0.09; 0.19] | 4.5% |
| Muftuoglu | -0.09 | 0.08 | 18 | -0.16 | 0.06 | 19 | | 0.07 | [0.02; 0.12] | 5.2% |
| Demircan | -0.10 | 0.30 | 101 | -0.20 | 0.30 | 35 | | 0.10 | [-0.02; 0.22] | 4.7% |
| Mastropasqua | -0.10 | 0.35 | 9 | -0.20 | 0.10 | 13 | | 0.10 | [-0.14; 0.34] | 3.5% |
| Bolubasi | -0.30 | 0.25 | 32 | -0.40 | 0.25 | 25 | - | 0.10 | [-0.03; 0.23] | 4.6% |
| Subtotal | | | 530 | | | 423 | + | -0.01 | [-0.09; 0.06] | 66.9% |
| Heterogeneity: /2 = 91% | 6 _, <i>p</i> < 0.01 | | | | | | | | | |
| Subgroup: RCT | | | | | | | | | | |
| Mishra | -0.23 | 0.32 | 50 | -0.10 | 0.41 | 50 | | -0.13 | [-0.27; 0.01] | 4.5% |
| Ozsaygili | -0.19 | 0.04 | 50 | -0.13 | 0.07 | 48 | | -0.06 | [-0.08; -0.04] | 5.3% |
| Podkowinski | -0.20 | 0.25 | 9 | -0.15 | 0.23 | 5 | | -0.05 | [-0.31; 0.21] | 3.3% |
| Maturi (2018) | -0.06 | 0.14 | 64 | -0.05 | 0.20 | 63 | | -0.01 | [-0.07; 0.05] | 5.2% |
| Maturi (2015) | -0.10 | 0.25 | 19 | -0.11 | 0.21 | 20 | | 0.01 | [-0.14; 0.16] | 4.5% |
| Shah | -0.11 | 0.12 | 23 | -0.12 | 0.15 | 27 | # _ | 0.01 | [-0.06; 0.08] | 5.1% |
| Kaya | -0.19 | 0.02 | 34 | -0.43 | 0.04 | 34 | | 0.24 | [0.22; 0.26] | 5.3% |
| Subtotal | | | 249 | | | 247 | * | 0.01 | [-0.10; 0.12] | 33.1% |
| Heterogeneity: /2 = 99% | 6 _, p < 0.01 | | | | | | | | | |
| Overall | | | 779 | | | 670 | + | -0.00 | [-0.06; 0.05] | 100.0% |
| Heterogeneity: /2 = 98% | 6 p < 0.01 | | | | | | | | | |
| Test for subgroup differ | ences: $\chi_1^2 = 0.14$ | 1, $df = 1 (p = 0)$ |).71) | | | | -0.4-0.2 0 0.2 0.4 0.6 0.8 | 1 | | |

Supplemental Material 18
Subgroup analysis
study design
CRT decrease

Subgroup analysis study design CRT decrease





Supplemental Material 19 Summary of OCT biomarker

| | Treatment | Hyperreflective | Hyperreflective dots (HRD) | Subfoveal serous | Change of choroidal | disorganization of inner |
|---------------|----------------|-------------------|------------------------------|----------------------------|-----------------------|--------------------------|
| Study | | dots (HRD) change | yes/no, after treatment(eye) | retinal detachment | thickness change (um) | retinal layers (DRIL) |
| | | (numbers) | | (SRD) change (um) | | (um) |
| Aksoy | 1. Aflibercept | | | | -92.94 | |
| et al | 2. Ozurdex | | | | -94.58 | |
| Bolubasi | 1. Bevacizumab | • | • | -110.69 | , | • |
| et al | 2. Ozurdex | | | -162.66* | | |
| Ceravolo | 1. Ranibizumab | -6.7 | | -37.4 | -1.9 | |
| et al | 2. Ozurdex | -13.22* | | -89.3* | -28.6 | |
| Demircan | 1. Ranibizumab | • | • | -133.6 | | |
| et al | 2. Ozurdex | | | -133.6 | | |
| Hernández-Bel | 1. Aflibercept | • | 10/5 | 5/10 (resolution after tx) | • | • |
| et al | 2. Ozurdex+ | | 7/8 | 7/6 (resolution after tx) | | |
| | Aflibercept | | | | | |
| Vujosevic | 1. Ranibizumab | -28 | | 5/10 (resolution after tx) | -9.3% | |
| et al 2017 | 2.Ozurdex | -32.4 | | 7/6 (resolution after tx) | -11.3% | |
| Vujosevic | 1. Ranibizumab | -5.94 | | -96.7% | | -80.52 |
| et al 2020 | 2.Ozurdex | -21.38* | | -86.8% | | -394.65 |

 $[\]ensuremath{^{*}}$ Ozurdex group had significant change comparing with Anti-VEGF group